Bibliografia UJ CM




Zapytanie: RUUD E
Liczba odnalezionych rekordów: 5



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wersja do druku | | | Nowe wyszukiwanie
1/5
P. Berlanga, C. Pasqualini, U. Potschger, C. Sanguesa, M.R. Castellani, A. Can˜ete, R. Luksch, M. Elliot, G. Schreier, M. Kropf, D. Morgenstern, V. Papadakis, S. Ash, E. Ruud, P. Brock, A[leksandra] Wieczorek, P. Kogner, T. Trahair, P. Ambros, T. Boterberg, V. Castel, D. Valteau-Couanet, R. Ladenstein.
Central nervous system relapse in high-risk stage 4 neuroblastoma : The HR-NBL1/SIOPEN trial experience.
European Journal of Cancer
2021 : Vol. 144, s. 1-8, il., bibliogr. 17 poz., abstr.
Autor korespondencyjny: P. Berlanga.
Open Access Creative Commons Attribution License CC-BY-NC-ND 4.0.

p-ISSN: 0959-8049

AZ
ORG
AIF
IF: 10.002
Adres url:
Streszczenie w PubMed:
2/5
R. Ladenstein, U. Poetschger, D. Valteau-Couanet, J. Gray, R. Luksch, W[alentyna] Balwierz, V. Castel, S. Ash, M. Beck-Popovic, G. Laureys, G. Chi Fung Chan, E. Ruud, K. Vettenranta, C. Owens, H. Schroeder, P. Ambros, S. Sarnacki, T. Boterberg, H. Lode.
Prognostic Risk Factors in the HR-NBL-1/SIOPEN Study in Patients Receiving Dinutuximab Beta (DB) Based Immunotherapy.
Pediatric Blood & Cancer
2020 : Vol. 67, suppl. 4, s. S265, abstr. 0586
Abstracts from the 52th Congress of the International Society of Paediatric Oncology (SIOP) Virtual Congress, October 14-17, 2020.
p-ISSN: 1545-5009

SZZ
SIF
Adres url:
3/5
L. Ladenstein, U. Poetschger, D. Valteau-Couanet, J. Gray, R. Luksch, W[alentyna] Balwierz, V. Castel, S. Ash, M. Beck-Popovic, G. Laureys, G. Chi Fung Chan, E. Ruud, K. Vettenranta, C. Owens, H. Schroeder, H. Loibner, P. Ambros, S. Sarnacki, T. Boterberg, H. Lode.
Early Results from the HR-NBL1/SIOPEN Trial Randomizing Dose-Reduced Subcutaneous Interleukin2 (SCIL2) with Dinutuximab Beta (DB) Long-Term Infusion (LTI) in High-Risk Neuroblastoma Patients.
Pediatric Blood & Cancer
2019 : Vol. 66, suppl. 4, s. S31-S32, abstr. FP049 SIOP19-0117
51st Congress of the International Society of Paediatric Oncology (SIOP), Lyon, France,October 23-26, 2019.
p-ISSN: 1545-5009

SZZ
SIF
4/5
R. Ladenstein, U. Poetschger, T. Boterberg, K. Dieckmann, S. Bolle, K. Holmes, S. Sarnacki, J. Gomez-Chacon, P. Brock, R. Luksch, S. Ash, W[alentyna] Balwierz, E. Ruud, V. Papadakis, C. Owens, J. Stenman, H. Schroeder, T. Trahair, D. Valteau-Couanet, M. Gaze.
Success of the HR-NBL1/SIOPEN Trial Local Control Strategy in High-Risk Neuroblastoma Patients Receiving High-Dose Therapy and Stem Cell Transplantation.
Pediatric Blood & Cancer
2018 : Vol. 65, suppl. 2, s. S261-S262, abstr. PO-372.
p-ISSN: 1545-5009

SZZ
SIF
5/5
R. Ladenstein, U. Poetschger, M. Elliot, R. Luksch, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W[alentyna] Balwierz, E. Ruud, P. Kogner, H. Schroeder, A. Forjaz de Lacerda, M. Beck-Popovic, P. Bician, M. Garami, T. Trahair, P. Ambros, K. Holmes, G. Schreier, M. Gaze, A. Pearson, D. Valteau-Couanet, SIOP Europe Neuroblastoma Grp.
Risk factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN TRIAL.
Bone Marrow Transplantation
2016 : Vol. 51, suppl. 1, s. S46, abstr. O072.
42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, Valencia, Spain, APR 03-06, 2016.
p-ISSN: 0268-3369

SZZ
SIF
  Wyświetl ponownie stosując format:
Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ